Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These relapses are driven by insufficient persistence of CAR T cells, allowing for antigen-positive B-ALL re-emergence and loss of the targeted epitope either in isolation or as part of lineage-switching.
Scientists from the Machine Intelligence from Cortical Networks (MICRONS) consortium have published the microconnectome of a cubic millimeter of the mouse brain. This is the most complete map of this organ to date at nanometer resolution for a mammal. It not only contains the structure and connections of each and every cell in that volume of tissue, but is also linked to the neuronal activity of that portion of the CNS, linking anatomy and function in the same cells.
Oxford University Innovation Ltd. has reported radiolabeled compounds reported to be useful for the diagnosis and treatment of cancer. An unlabeled form of an exemplified compound ([68Ga]-KK02 pg 33) inhibited PARP1 activity (IC50=9.1 nM).
A Suven Life Sciences Ltd. patent has detailed new N-aryl benzamide derivatives acting as P2X purinoceptor 7 (P2RX7; P2X7) antagonists. As such, they are believed to be potentially useful for the treatment of cancer, pain, renal, neurological, endocrine and psychiatric disorders.
Work at Vir Biotechnology Inc. has led to the identification of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).
Aurigene Oncology Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising a protein cereblon (CRBN)-binding moiety covalently bound to a CREB-binding protein (CREBBP; CBP)-targeting moiety through a linker.
Several recent Atavistik Bio Inc. patents describe substituted aminopyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors, particularly AKT1 (E17K mutant) reported to be useful for the treatment of cancer.
When an autoimmune disease disrupted the life of someone close to scientist Dario Gutierrez, an idea emerged for a new company called Merida Biosciences focused on removing misdirected antibodies and their negative effects using Fc biotherapeutics.
Neddylation is a post-translational modification that conjugates the NEDD8 protein to protein substrates, such as the cullins, which once neddylated join complex to form cullin-RING ubiquitin E3 ligases (CRLs), which in turn play a crucial role in regulating proteasomal degradation. The University of Kentucky has presented preclinical data on their neddylation inhibitor TK-59 as a cancer therapeutic.
RSS
